Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from BriaCell Therapeutics ( (TSE:BCT) ) is now available.
BriaCell Therapeutics’ pivotal Phase 3 trial of its lead immunotherapy candidate Bria-IMT in metastatic breast cancer has been highlighted by Nature Medicine as one of the “clinical trials to watch in 2026,” underscoring rising scientific and clinical interest in the program. The BRIA-ABC study, which compares Bria-IMT plus an immune checkpoint inhibitor against physician’s choice therapy in a broad, real‑world metastatic breast cancer population, has screened more than 230 patients and enrolled over 160 to date, with top-line data expected as early as the first half of 2026 and an interim overall survival analysis planned after 144 events; positive results could support full regulatory approval and commercialization of Bria-IMT, potentially strengthening BriaCell’s position in the oncology immunotherapy market.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$40.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel cell-based immunotherapies to transform cancer care, with a lead program targeting metastatic breast cancer. The company’s primary product candidate, Bria-IMT, is being advanced through late-stage clinical development with an emphasis on addressing heavily pre-treated patient populations across all breast cancer subtypes.
Average Trading Volume: 4,265
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$22.7M
For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.